Many studies have investigated the effects of CYP1B1 polymorphisms in modifying BC risk [16], due to its role in production of 4-OH-E2, a potential carcinogenic estrogen metabolite, and the activation of a number of environmental carcinogens. This evidence concerns the gene CYP1B1 and breast cancer.